The associate professor of genetics at Yale University School of Medicine is targeting genes that can supercharge CAR T cells against cancer. CAR T-cell therapy is effective for many patients with blood cancers – which led to the FDA approving six therapies since 2017 – but scientists are still researching how to make effective CAR T cells for solid tumors.
Research Fellow′s technology can create CAR T cells inside patients.
Matthias Stephan, MD, PhD
The current process for CAR T-cell therapy can take weeks, with patients’ T cells removed, sent to a laboratory, enhanced with a chimeric antigen receptor (CAR), sent back to the hospital and infused back into the patients.
Matthias Stephan, MD, PhD, an Alliance for Cancer Gene Therapy Research Fellow, is creating a way to speed up the process using injected mRNA to engineer T cells into CAR T cells as they circulate within the body.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.